ViaScint may help cardiac bypass patient selection
This article was originally published in Clinica
Executive Summary
First results from Phase III trials with Medco Research's (US) imaging agent, ViaScint, suggest it can predict which patients will have improved cardiac function following revascularisation. The multicentre trials involving 200 patients in the US and Canada "are the first large multicentre prospective studies to evaluate residual myocardial viability in a population known for the complexity of its clinical presentation," says Cesare Orlandi, executive R&D director of Medco.